Using sildenafil to treat early pulmonary vascular disease in scleroderma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase II trial investigates the effectiveness of sildenafil in treating patients with scleroderma who have mildly elevated pulmonary pressures. The study is randomized, double-blind, and placebo-controlled, aiming to assess improvements in pulmonary function and overall health. Participants will receive either sildenafil or a placebo, and their responses will be monitored through various clinical assessments. The goal is to determine if sildenafil can provide significant benefits for this specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Previous documentation of mean pulmonary artery pressure between 21 and 24 mm Hg with a pulmonary capillary wedge pressure (or left ventricular end-diastolic pressure) ≤ 15 mm Hg within six months before study entry.
* Diagnosis of SSc according to 2013 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) classification criteria.
* Pulmonary function tests with forced expiratory volume in one second/forced vital capacity (FEV1/FVC) \>50% AND either a) total lung capacity (TLC) or forced vital capacity (FVC) \> 70% predicted or b) TLC or FVC between 60% and 70% predicted with no more than mild interstitial lung disease on computerized tomography scan of the chest on studies obtained within 6 months of enrollment.
* Ventilation perfusion scan or computed tomography with intravenous contrast (CT angiogram) without evidence of chronic thromboembolism at anytime before study entry.
* Ability to perform six minute walk testing without significant limitations in musculoskeletal function or coordination.
* Informed consent.

Exclusion Criteria:

* World Health Organization (WHO) Class IV functional status.
* Systolic blood pressure less than 90 mmHg at screening visit prior to enrollment.
* Clinically significant untreated sleep apnea.
* Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection fraction \< 45% on most recent echocardiography (within 1 year).
* Use of Pulmonary Arterial Hypertension (PAH) therapy (prostacyclin analogues, endothelin-1 receptor antagonists,phosphodiesterase-5 inhibitors, riociguat, selexipag) within the past 3 months.
* Hospitalized or acutely ill.
* Renal failure (creatinine above 2.0) at screening visit.
* Enrollment in a clinical trial or concurrent use of another investigational drug (non FDA approved) or device therapy within 30 days of screening visit.
* Age \< 18.
* Currently pregnant.
* Current use of nitrates.

Where it's running

• Johns Hopkins
  Baltimore, Maryland, United States Recruiting
• Louisiana State University
  New Orleans, Louisiana, United States Not yet recruiting

Study contacts

• Principal investigator: Stephen Mathai, MD — Johns Hopkins University
• Study coordinator: Stephen Mathai, MD
• Email: smathai4@jhmi.edu
• Phone: 4106146311

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-in-human test of PRO-203 in healthy adults and people with systemic sclerosis

  Researchers will test a single subcutaneous dose of PRO-203 in healthy adults and in people with systemic sclerosis to see if it is safe and how the body handles it.

  Recruiting at 12 sites Phase 1/2 Prolium Bioscience, Inc · Melbourne, Victoria and 12 other locations · NCT07641634

• EVM18001 for adults with refractory lupus, myasthenia gravis, and scleroderma

  This single-arm study will test an experimental CAR‑T therapy called EVM18001 to see if it is safe and helps adults whose lupus, myasthenia gravis, or scleroderma did not respond to standard treatments.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07470151

• Biopsychosocial (BETY) exercise program for children and adults with scleroderma

  This project will test whether BETY, a biopsychosocial exercise program, helps children and adults with scleroderma improve physical function and psychosocial well-being.

  Recruiting Hacettepe University · Ankara, Altındağ · NCT07292961

• Transcriptomic analysis of skin fibroblasts in scleroderma

  This project will analyze gene activity in skin fibroblasts from people with systemic scleroderma and from surgical controls to see if fibroblasts contribute to the disease.

  Recruiting Centre Hospitalier Universitaire Dijon · Dijon · NCT07256418

• Physical performance and daily function in people with scleroderma

  This project will test which questionnaires and simple physical tests best measure physical performance and daily functioning in children and adults with scleroderma.

  Recruiting Hacettepe University · Çankaya, Ankara · NCT07183072

• Chewing and swallowing performance in people with scleroderma

  This project will see how children and adults with scleroderma chew and swallow and collect biopsychosocial information using questionnaires.

  Recruiting Hacettepe University · Çankaya, Ankara · NCT07182981

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.